Our company has received notification from the patent office that the patent certificate for "Composition for Upper Respiratory Tract Drug Delivery and Its Administration Method" has been granted in China, with application number 202211335382.4.
Our company has signed a contract with Company S, which focuses on the cross-strait medical aesthetics market. Through our nano-emulsion technology, we will assist Company S in developing a sustained-release vitamin C+E product. Subsequently, Original BioMedical will exclusively supply the core raw materials.
Original BioMedicals is a specialized technology platform company for innovative drug development and pharmaceutical development services, possessing strong research capabilities and a wealth of product resources. Xinbai Pharmaceutical is a subsidiary of China Resources Pharmaceutical Group, while Rongchang Pharmaceutical is a professional pharmaceutical distributor. Adhering to the principles of win-win cooperation and joint development, the three parties will leverage their respective strengt
Our company has obtained an Australian invention patent for the "Composition for Upper Respiratory Tract Drug Delivery and Its Administration Method," with certificate number 2022259787.
Our company has obtained a Japanese invention patent for "Composition for Upper Respiratory Tract Drug Delivery and Its Administration Method," with certificate number Patent No. 7514898.
Today (29th), Origin Biomedical (6483) debuted on the Emerging Stock Market at a reference price of NT$20 per share, focusing on the development of multiple 505(b)(2) new drugs. These include OBM-B01 for the prevention and treatment of cyanide poisoning from fire inhalation, as well as OBM-A01 for the prevention and treatment of radiation injuries.
